Clinical Cancer Research, Vol 4, Issue 12 2999-3004, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity

M Kouwaki, N Hamajima, S Sumi, M Nonaka, M Sasaki, K Dobashi, K Kidouchi, H Togari and Y Wada
Department of Pediatrics, Nagoya City University Medical School, Nagoya, Japan. kouwaki@med.nagoya-cu.ac.jp

5-Fluorouracil (5-FU) is used widely in the treatment of several common neoplasms. Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the catabolism of 5-FU. Several recent studies have described a pharmacogenetic disorder in which cancer patients with decreased DPD activity develop life-threatening toxicity following exposure to 5-FU. We reported recently the first Japanese case of decreased DPD activity accompanied by severe 5-FU toxicity. The present study describes the results of molecular analysis of this patient and her family, in which three novel mutations (Arg21Gln, Val335Leu, and Glu386Ter) of the gene coding for DPD were identified. We also revealed that Arg21Gln and Glu386Ter are on the same allele and that Val335Leu is on the other allele, on the basis of analysis of the family genome. Expression analysis in Escherichia coli showed that Val335Leu and Glu386Ter led to mutant DPD protein with significant loss of enzymatic activity and no activity, respectively. The Arg21Gln mutation, however, resulted in no decrease in enzymatic activity compared with the wild type. The present data represent the first molecular genetic analysis of DPD deficiency accompanied by severe 5-FU toxicity in a Japanese patient.

This article has been cited by other articles:

				A. Morel, M. Boisdron-Celle, L. Fey, P. Soulie, M. C. Craipeau, S. Traore, and E. Gamelin Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol. Cancer Ther., November 1, 2006; 5(11): 2895 - 2904. [Abstract] [Full Text] [PDF]

				K. Ogura, T. Ohnuma, Y. Minamide, A. Mizuno, T. Nishiyama, S. Nagashima, M. Kanamaru, A. Hiratsuka, T. Watabe, and T. Uematsu Dihydropyrimidine Dehydrogenase Activity in 150 Healthy Japanese Volunteers and Identification of Novel Mutations Clin. Cancer Res., July 15, 2005; 11(14): 5104 - 5111. [Abstract] [Full Text] [PDF]

				H. Ezzeldin, M. R. Johnson, Y. Okamoto, and R. Diasio Denaturing High Performance Liquid Chromatography Analysis of the DPYD Gene in Patients with Lethal 5-Fluorouracil Toxicity Clin. Cancer Res., August 1, 2003; 9(8): 3021 - 3028. [Abstract] [Full Text] [PDF]

				M. Raida, W. Schwabe, P. Hausler, A. B. P. Van Kuilenburg, A. H. Van Gennip, D. Behnke, and K. Hoffken Prevalence of a Common Point Mutation in the Dihydropyrimidine Dehydrogenase (DPD) Gene within the 5'-Splice Donor Site of Intron 14 in Patients with Severe 5-Fluorouracil (5-FU)- related Toxicity Compared with Controls Clin. Cancer Res., September 1, 2001; 7(9): 2832 - 2839. [Abstract] [Full Text] [PDF]

				A. B. P. van Kuilenburg, E. W. Muller, J. Haasjes, R. Meinsma, L. Zoetekouw, H. R. Waterham, F. Baas, D. J. Richel, and A. H. van Gennip Lethal Outcome of a Patient with a Complete Dihydropyrimidine Dehydrogenase (DPD) Deficiency after Administration of 5-Fluorouracil: Frequency of the Common IVS14+1G>A Mutation Causing DPD Deficiency Clin. Cancer Res., May 1, 2001; 7(5): 1149 - 1153. [Abstract] [Full Text]

				A. B. P. van Kuilenburg, J. Haasjes, D. J. Richel, L. Zoetekouw, H. Van Lenthe, R. A. De Abreu, J. G. Maring, P. Vreken, and A. H. van Gennip Clinical Implications of Dihydropyrimidine Dehydrogenase (DPD) Deficiency in Patients with Severe 5-Fluorouracil-associated Toxicity: Identification of New Mutations in the DPD Gene Clin. Cancer Res., December 1, 2000; 6(12): 4705 - 4712. [Abstract] [Full Text]

				A. B.P. Van Kuilenburg, H. Van Lenthe, A. Tromp, P. C.J. Veltman, and A. H. Van Gennip Pitfalls in the Diagnosis of Patients with a Partial Dihydropyrimidine Dehydrogenase Deficiency Clin. Chem., January 1, 2000; 46(1): 9 - 17. [Abstract] [Full Text] [PDF]

				C. J. Allegra Dihydropyrimidine Dehydrogenase Activity: Prognostic Partner of 5-Fluorouracil? Clin. Cancer Res., August 1, 1999; 5(8): 1947 - 1949. [Full Text] [PDF]